Silexion Therapeutics Corp (SLXN) Fair Value 2026

SLXN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.4 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-08-28, Silexion Therapeutics Corp (SLXN) trades at $0.36. QOC: 5.4/10. Value Trap Risk: 25/100 (LOW). 1/13 models active.

Key Facts

Ticker
SLXN
Price
$0.36
Quality Score
5.4/10
Value Trap Risk
25/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +94.1% upside with 28% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give SLXN?

1 Intrinsic Value Models vs. Current Price ($0.36)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.70 +94.1%

All Models Active

All 1 models are displayed above.

What Is Silexion Therapeutics Corp (SLXN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Silexion Therapeutics Corp's intrinsic value is estimated at a median fair value of $0.70. At a current market price of $0.36, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +94.1%.

What Do the Models Say About SLXN?

1 of 13 models are currently active for SLXN. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does SLXN Rank in Biotechnology?

Among 625 Biotechnology stocks, SLXN ranks #238 by Quality of Company score. CirclFi's QOC score of 5.4/10 evaluates 32 fundamental signals. A score of 5.4 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Silexion Therapeutics Corp operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating SLXN should weigh these sector-specific dynamics alongside our model-derived fair values.

Is SLXN a Value Trap?

CirclFi's Value Trap algorithm assigns SLXN a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Silexion Therapeutics Corp. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Silexion Therapeutics Corp's fundamental quality profile registers 5.4/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SLXN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SLXN's 1 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Silexion Therapeutics Corp Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

MANEVeradermics, IncorporatedQOC 5.4RMTGRegenerative Medical Technology Group Inc.QOC 5.4NBPNovaBridge BiosciencesQOC 5.4PULMPulmatrix, Inc.QOC 5.4HYPDHyperion DeFi, Inc.QOC 5.4ANEBAnebulo Pharmaceuticals, Inc.QOC 5.4LRMRLarimar Therapeutics, Inc.QOC 4.7BCLIBrainstorm Cell Therapeutics Inc.QOC 3.8ZEOXZeo ScientifiX, Inc.QOC 6.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: MANE · RMTG · NBP · PULM · HYPD · ANEB · LRMR · BCLI · ZEOX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SLXN?

6 companies across all industries closest to SLXN’s Quality of Company score of 5.4/10.

CDLXCardlytics, Inc.QOC 5.4SCKTSocket Mobile, Inc.QOC 5.4RYETRuanyun Edai Technology Inc.QOC 5.4MGNOMagnolia Bancorp, Inc.QOC 5.4ORIOOrion Digital Corp.QOC 5.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CDLX · SCKT · RYET · MGNO · ORIO · NVDA

Where Does SLXN Sit in CirclFi's Biotechnology Rankings?

SLXN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Silexion Therapeutics Corp’s Valuation?

What is Silexion Therapeutics Corp's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Silexion Therapeutics Corp (SLXN). The Quality of Company score is 5.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SLXN overvalued or undervalued right now?

At $0.36, 1 of 1 active models suggest SLXN may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Silexion Therapeutics Corp's business model in Biotechnology.

What does a Quality of Company score of 5.4 mean for SLXN?

Silexion Therapeutics Corp's QOC of 5.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SLXN?

CirclFi analyzes SLXN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is SLXN a value trap in 2026?

Silexion Therapeutics Corp's Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Silexion Therapeutics Corp (SLXN) a Quality of Company score of 5.4/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SLXN/ · Methodology
Primary sources for this SLXN valuation
  • Financial statements: Silexion Therapeutics Corp 10-K and 10-Q filings on SEC EDGAR (CIK 0002022416) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SLXN as of ; valuations recomputed .